PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-488.33%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-14.77%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-14.77%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-25.91%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
18928.57%
D&A change of 18928.57% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
439.10%
EBITDA change of 439.10% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
10.94%
Income change of 10.94% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
70.03%
Other expenses change of 70.03% versus flat Biotechnology. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.20%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
11.95%
Income change of 11.95% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
11.92%
EPS growth exceeding 1.5x Biotechnology median of 5.00%. Joel Greenblatt would investigate advantages.
11.92%
Diluted EPS growth exceeding 1.5x Biotechnology median of 5.26%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.